Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Respiratory Disease Vaccine Market Be Worth By 2029?

The market size for vaccines for respiratory diseases has observed a slight increase in the past few years. The market is projected to expand from $69.99 billion in 2024 to $70.03 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 0.1%. The growth during the historical period is a result of the escalating occurrence of respiratory infections, heightened awareness about vaccinations in the public sector, initiatives in public health, and an upswing in the demand for more potent and better-tolerable vaccines.

The market size of the respiratory disease vaccine is projected to experience consistent expansion in the coming years. It is forecasted to augment to “$77.48 billion by 2029, with a compound annual growth rate (CAGR) of 2.6%. The escalation anticipated during this forecast period can be credited to the aging demographic, surge in healthcare expenditure, investment in vaccines, and readiness for pandemics. Key tendencies to watch in the forecast period encompass vaccine innovation, co-operative scientific research, progression in vaccine formulation, and endorsement of drugs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12924&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Respiratory Disease Vaccine Market?

The respiratory disease vaccine market is projected to grow due to the rising prevalence of tuberculosis. Tuberculosis (TB) is an infectious respiratory condition caused by Mycobacterium tuberculosis bacteria, primarily attacking the lungs and other organs leading to various health complications. The uptick in tuberculosis rates might incentivize the development and distribution of vaccines for the respiratory disease in a bid to curb its spread. For example, the Centers for Disease Control and Prevention, a governmental organization in the US, stated in November 2023 that there were 8,331 reported tuberculosis cases in the United States in 2022, a 5.9% surge from the previous year. The infection rate jumped to 2.5 cases per 100,000 individuals, a 5.5% growth from the previous year. Therefore, the escalating rates of tuberculosis will stimulate the growth of the respiratory disease vaccine market.

What Are The Primary Segmentation Parameters In The Respiratory Disease Vaccine Market?

The respiratory disease vaccine market covered in this report is segmented –

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine

2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections

3) By Age: Infant, Adolescent, Adult

4) By End-User: Clinic, Hospital, Other End-Users

Subsegments:

1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine

2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine

3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine, MMRV

Which Emerging Trends Are Reshaping The Respiratory Disease Vaccine Market Landscape?

Key players in the respiratory disease vaccine market are focusing their efforts on the development of cutting-edge products to enhance their effectiveness and provide advanced solutions for the prevention and treatment of respiratory diseases. For example, Pfizer Inc., a pharmaceutical firm based in the United States, received approval from the Food and Drug Administration (FDA) in May 2023 for ABRYSVO (Respiratory Syncytial Virus Vaccine). This is a bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine aimed at preventing lower respiratory tract problems caused by the respiratory syncytial virus in those aged 60 and over. ABRYSVO comprises two preF proteins specifically designed to optimize immunity against RSV A and B strains and has been clinically demonstrated to be safe and effective.

Which Organizations Are At The Forefront Of The Respiratory Disease Vaccine Market?

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Which Region Holds The Greatest Opportunity For Respiratory Disease Vaccine Market Expansion?

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12924&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model